Scientific Program

Conference Series Ltd invites all the participants across the globe to attend International Conference on Pulmonology and Critical Care Medicine Las Vegas, Nevada, USA.

Day 2 :

Keynote Forum

Islam Ibrahim

University of California, USA

Keynote: TBA

Time : 09:15-09:45

Pulmonary Disorders 2017 International Conference Keynote Speaker Islam Ibrahim photo
Biography:

Dr. Islam Ibrahim is a pulmonologist in San Diego, California. He received his medical degree from Cairo University School of Medicine and has been in practice for more than 20 years. His Clinical interest are are in Global Challenges in Treating COPD, Diffuse, Interstitial Lung Disease and Upper airway dysfunction induced dyspnea. His investigative interest are in
*Tissue Culture techniques
*TGF-BETA effect on the chemically injured retina
*Effect of various growth factors on the Regeneration of the    Pigmented 
*Epithelium in the White New Zealand Rabbit and
*Nocardiasis in  HIV + Pleural Effusion

Abstract:

Keynote Forum

Charles Grodzin

Emory University Hospital Midtown, USA

Keynote: TBA

Time : 09:45-10:15

Pulmonary Disorders 2017 International Conference Keynote Speaker Charles Grodzin photo
Biography:

Dr. Charles Grodzin completed his undergraduate education at Emory College graduating in 1986. He then completed medical school at Rush Presbyterian St. Luke’s medical center in Chicago Illinois in 1990. Subsequently, Dr. Grodzin completed his internship at Rush in 1991 and was awarded honors as Intern of the Year. Dr. Grodzin remained to complete his internal medicine residency culminating in being named chief resident in 1994. Dr. Grodzin then completed subspecialty training in pulmonary and critical care medicine at Rush. It was during this period that Dr. Grodzin was the lead editor of Diagnostic Strategies For Internal Medicine, a case based textbook of internal medicine. 

Upon completion of his training, Dr. Grodzin entered into private practice at the Elmhurst Clinic in Elmhurst Illinois attending in pulmonary and critical care medicine at Elmhurst Memorial Hospital for three years. In 2000, Dr. Grodzin left the Elmhurst Clinic to join Asthma and Respiratory Consultants near Dallas, Texas. In 2007, Dr. Grodzin was amongst a small group of physicians who supervised and administered the creation of a physician owned long-term acute care hospital, The Atrium, in Corinth, Texas.  In 2006, Dr. Grodzin established North Texas Pulmonary, a single physician practice providing pulmonary and critical care consultative service to the North Dallas region. Between 2000 and 2014 Dr. Grodzin attended at three acute care hospitals and two long-term acute care hospitals during this period including serving as medical director for critical care and various ICUs in the area.  In May 2014, Dr. Grodzin closed North Texas Pulmonary to take a position as Assistant Professor of Medicine at Emory University based at the Emory University Hospital Midtown campus.

Dr. Grodzin practices general pulmonary medicine and critical care. He sees patients in the Emory Clinic at the Emory University Hospital Midtown campus as well as attends on the Pulmonary Medical Consult Service and in the Intensive Care Unit.  He is the current Medical Director of the Medical Intensive Care Unit and The Department of Respiratory Therapy.  He has championed bedside critical care ultrasound and critical decision making, re-organization and integration of multi-disciplinary rounds in the critical care unit and is the EUHM lead physician for the Sepsis care and has been instrumental in taking measures to prevent hospital acquired infection in the ICU specifically focusing on bladder catheters and central venous access lines.

In addition, Dr. Grodzin’s focus includes providing outstanding medical education in the school of medicine and the Department of Internal Medicine giving didactic pulmonary and critical care lectures as well as participating in case conference discussions aimed at teaching both basic and advanced elements of pulmonary and critical care medicine.  Along with colleagues at Midtown, Dr. Grodzin assisted in organizing the monthly faculty case conference wherein complex pulmonary medical matters are discussed sharing varied clinical knowledge and experience amongst the group.  

Dr. Grodzin is delighted to have the opportunity to be a member of the Emory University Hospital and School of Medicine medical staff and faculty and is proud to have come full circle back to Atlanta and Emory University.

 

Abstract:

Keynote Forum

Alaa eldin Thabet Hassan Abdelmaaboud

Yanbu Saudia Arabia Royal Commission, KSA

Keynote: TBA
Pulmonary Disorders 2017 International Conference Keynote Speaker Alaa eldin Thabet Hassan Abdelmaaboud photo
Biography:

Abstract:

  • Environmental Pulmonary Diseases | Lung Diseases | Pleural Effusion | Pulmonary Embolism | Sleep Apnea | Pulmonary Research | Pulmonary Rehabilitation | Novel Approach and Therapies
Location: Bora Salon

Chair

Shahid Sheikh

Ohio State University College of Medicine, USA

Session Introduction

Samah M Elaidy

Suez Canal University, Egypt

Title: Title: Serotonin Receptor Subtype-2 and Idiopathic Pulmonary Fibrosis

Time : 11:25-11:45

Speaker
Biography:

Samah M. Elaidy, MD, PhD (2012), is a lecturer of clinical pharmacology, school of medicine, Suez Canal University (SCU), Egypt. She is a member of educational curricula and medical research committees, in addition to National Authority for Quality Assurance and Accreditation of Education committee at Faculty of Medicine, SCU, also a member of the Egyptian Society of Pharmacology and Experimental Therapeutics. Dr.Elaidy has taught graduate and undergraduate clinical pharmacology courses at SCU, Portsaid University, and Libyan International University. She holds certificates in research methodology of grant writing and in human resource development in health management and leadership, and awarded certificate of appreciation for international publications (SCU, 2012-2013). Dr.Elaidy was a speaker, and a member of the scientific committee in several national and international conferences and workshops. Her areas of expertise are pulmonary, gastrointestinal, renal, cancer and nanotechnology pharmacological researches with published articles and works in progress project.

Abstract:

Augmentation of lung serotonin (5-hydroxytryptamine, 5-HT) content is evident during development of pulmonary fibrosis with the implication of highly expressed metabotropic 5-HT2 receptors in the pathogenesis, ending in various mitogenic and profibrotic effects. In the fibrotic lung microenvironment, three 5-HT2 receptors subtypes- A, B, C- are recognized. The 5-HT2A and 5-HT2B receptors are chiefly confined to fibroblasts, alveolar epithelial cells, with an augmented allocation of 5-HT2C receptors into alveolar macrophages. These unique allocations allow multiple intersecting serotonergic pathways, which modulate different fibro-proliferative and angiogenic key regulators in fibrotic lung microenvironment. Recently in lung fibrosis, 5-HT2C has been found to play a major phenotypical alternating role on alveolar macrophage with subsequent progression into inflammatory-fibrotic cascades. In several recent studies, selective specified pharmacological antagonism of 5-HT2A and/or 2B and/or 2C receptors was found to attenuate bleomycin-induced lung injury and fibrosis through improving lung functions, decreasing lung edema and downregulating several collagen deposition mediators, as tumor necrosis factor-α (TNF-α), transforming growth factor-β1 (TGF-β1), connective tissue growth factors (CTGF), plasminogen activator inhibitor-1 (PAI-1), monocyte chemoattractant protein-1 (MAP-1) and vascular endothelial growth factor (VEGF). In conclusion, blockade of 5-HT2A, 2B, and 2C receptors is considered a promising molecular target for pharmacological intervention in fibro-proliferative interstitial lung diseases. However, further studies are needed to explore in depth the complexity of roles played by different 5-HT2 receptor subtypes and the therapeutic implications of antagonizing their effects in idiopathic pulmonary fibrosis.

Keywords:  5-HT2A; 5-HT2B; 5-HT2C; Bleomycin;    Cyproheptadine; Idiopathic pulmonary fibrosis; Mirtazapine; RS-102221; Serotonin; Terguride.

Charudatt Shirwadkar

Blacktown Hospital, Australia

Title: TBA
Speaker
Biography:

Dr Charudatt Shirwadkar is an Australian-based health professional at Blacktown Hospita. He did his FCICM from the College of Intensive Care Medicine, Australia & New Zealand
Dr. Charudatt is trained as a Intensive Care Specialist since from the year of 2009

Abstract:

Shahid Sheikh

Ohio State University College of Medicine, USA

Title: Title: Asthma diagnosis management and role of nursing

Time : 11:45-12:05

Speaker
Biography:

Dr Shahid Sheikh, MD is currently working as an Associate Professor of Pediatrics at Ohio State University College of Medicine in the Divisions of Pulmonary Medicine and Allergy & Immunology. He is also working in the department of Pediatrics in the Nationwide Children’s Hospital, 700 Children’s Drive, Columbus Ohio. USA
 

Abstract:

Asthma is a common chronic disease of childhood.  In the United States alone, asthma affects about 5 million children, with an estimated annual cost of more than $4 billion and prevalence of asthma is rising.   Adoption and adherence to asthma guidelines is still less than optimal.   Strategies to improve clinical outcomes depend heavily on educating primary care physicians. In busy primary care practices, physicians lack time educate parents on preventive asthma management plans.  Thus it is important that, in addition to physicians, other medical personnel such as nurses and nurse practitioners be a part of patient/family education to improve self-management of asthma.  Once trained, they can help implement preventive clinical management plans, educate patients and families, and ensure that patients are on appropriate therapies to achieve adequate asthma control.

We are working on this model for last four years at our Institution and I can share results and outcomes.

Speaker
Biography:

Carmen W H Chan has complete BSN, MPhil, RN and PhD. Dr. Carmen has won University Education Award, The Chinese University of Hong Kong, November, 2016 and Sigma Theta Tau International Honor Society of Nursing Excellence in Research Award, April 7, 2014.She is a pioneered biological nursing study on lung disease to identify biomarkers for early detection of the inflammation process and symptom control and successfully obtained an external competitive grant to pursue the study. Professor Carmen Chan has demonstrated integrated scholarship in pediatric, cancer and palliative care research which has broadly impacted on the profession, patients, families, community, and nursing education. Her main fields of research specialization include symptom management, psychosocial care, sexuality, advance care planning, pediatric care and cancer screening.

As 'symptom cluster' has been acknowledged to be at the cutting edge of science in symptom management, Professor Chan’s early PhD work on the identification and management of 'symptom cluster' in patients with cancer was novel and contributed to the international development of nursing knowledge. It also laid a foundation for her subsequent studies on symptom management including the treatment of oral mucositis, skin rash, breathlessness, fatigue, nausea and vomiting, pain, anxiety and sexual function.

Professor Chan's palliative care research focuses on the promotion of advance care planning and advance directives, and targets on cancer patients, pediatric patients, older adults and the general public. Her research initiatives on this area have demonstrated excellence in design and innovation, and a great impact on the health care profession and the society. Professor Chan and her team conducted several community roadshows and surveys to promote advance care planning and advance directives in Hong Kong. Subsequently, they developed and published a health manual for advance care planning, which has been widely distributed to the public via community roadshows and to elderly centers and hospitals. In 2016, Professor Chan will launch another GRF project to carry out a large-scale population survey on the acceptance and completion of advance directive among the general public in Hong Kong

Abstract:

Background: Silicosis is a prolonged, irreversible and incurable occupational disease. For better control of this deadly disease, effective and significant biomarkers could be crucial. This study showed the possible immediate molecular pathogenic events in lung epithelial cells underlying sub-lethal silica exposure from 30 minutes to 24 hours, using the high-throughput RNA-Seq approach.

Method: A549 cells were treated with crystalline silica at 20% cytotoxicity (max.) to allow the investigation of the inflammatory and fibrotic effects of silica particles. Then, total RNA was extracted and mRNA was enriched using the ribosomal RNA depletion kit. The enriched mRNA was reverse-transcribed to prepare transcriptome library for RNA-Seq analysis in an Illumina HiSeq2000 genetic analyzer. The filtered transcriptome sequence data generated was assembled and mapped to the human reference genome to determine the differentially expressed genes. Significant differentially expressed candidate genes will be verified by real-time PCR followed by comprehensive pathway analysis using DAVID 6.7.

Results: From the RNA seq results, it was found that several molecular pathways were significantly highlighted in silica exposed cellular changes. These include known pathways for silicosis such as inflammatory responses and oxidative stress responses. Other mechanisms on transcription factor regulation, aldehyde dehydrogenase and blood vessel development was newly reported to be associated with silicosis. The changes of expression level of genes under these pathways were confirmed by quantitative PCR (qPCR). In future, it is important to characterize the relationship of newly found pathways and silicosis in order to discover the novel biomarkers.

Conclusion: In this study, by RNA sequencing analysis, several pathways on transcription factor regulation, aldehyde dehydrogenase and blood vessel development were newly described to be involved in silica treatment on lung cells. Hopefully, novel biomarkers of silicosis could be discovered in future.